Business
Year-end Report - January-December 2025
STOCKHOLM – 13 February 2025. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Year-end Report January-December 2025. The full report is available on the Company's website. “A stronger financial position under a new flag means we are well-positioned to continue supporting our portfolio companies in their efforts to develop new treatments in areas with substantial medical need”, says Viktor Drvota, CEO, KDventures. Significant events during the fourth quarter The portfolio company Dilafo
About this update from Kdventures Ab Class B
[{"type":"image","alt":"Karolinska Development AB (publ)","displaySize":"","headline":null,"caption":"Karolinska Development AB (publ)","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/2e2c1945689d928e88e45887cdae0a00"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zUAV0MXjqZudrDV2mwixyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2e2c1945689d928e88e45887cdae0a00","width":300,"height":38},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/zUAV0MXjqZudrDV2mwixyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2e2c1945689d928e88e45887cdae0a00","width":300,"height":38}},"lazy":false},{"type":"text","content":"STOCKHOLM – 13 February 2025. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Year-end Report January-December 2025. The full report is available on the Company's website.","length":185,"tagName":"p"},{"type":"text","content":"“A stronger financial position under a new flag means we are well-positioned to continue supporting our portfolio companies in their efforts to develop new treatments in areas with substantial medical need”, says Viktor Drvota, CEO, KDventures.","length":244,"tagName":"p"},{"type":"text","content":"Significant events during the fourth quarter ","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The portfolio company Dilafor was granted a patent in the US, protecting its drug candidate tafoxiparin for its main target indication, priming of labor. The patent will serve as a key asset as Dilafor advances into phase 3 clinical development of tafoxiparin (October 2025).","length":275,"tagName":"p"}]},{"val":[{"type":"text","content":"The portfolio company PharmNovo received approval from the Spanish regulatory authorities to initiate a phase 2a clinical trial of its drug candidate, PN6047, being developed as a treatment for neuropathic pain. The trial will be conducted in the EU, but has been fully aligned with the requirements defined by the U.S. Food and Drug Administration (FDA), earlier this year (October 2025).","length":389,"tagName":"p"}]},{"val":[{"type":"text","content":"The portfolio company SVF Vaccines presented positive results from a preclinical study of its immunotherapy SVF-001...